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Interleukin-10 inhibits ischemic and cisplatin-induced acute Acute renal failure (ARF) is caused by ischemic and
renal injury. nephrotoxic insults acting alone or in combination [1, 2].
Background. Acute renal failure (ARF) is caused by isch- Ischemic injury is present in about 50% of patients with
emic and nephrotoxic insults acting alone or in combination.
acute renal failure, and is thought to be responsible forAnti-inflammatory agents have been shown to decrease renal
much of the non-immunologic injury that occurs in theischemia-reperfusion and cisplatin-induced injury and leuko-
cyte infiltration. Interleukin-10 (IL-10) is a potent anti-inflam- immediate days following renal transplantation [1, 3].
matory cytokine that inhibits inflammatory and cytotoxic path- Methods to inhibit post-transplant ARF might allow
ways implicated in acute renal injury. Therefore, we sought to transplantation from marginal donors, and hence, de-
determine if IL-10 inhibits acute renal injury. crease the waiting time for a renal transplant.Methods. The effects of IL-10 were studied in mice following
Cisplatin is one of the most effective chemotherapeu-cisplatin administration and bilateral renal ischemia-reperfu-
tic agents for the treatment of solid tumors includingsion, in a rat model of renal transplantation, and in cultured
mouse cortical tubule cells. ovarian carcinomas, head and neck carcinomas, and
Results. IL-10 significantly decreased renal injury following germ cell tumors. The anti-tumor effects of cisplatin are
cisplatin administration and following renal ischemia/reperfu- dose-related; intensification of the dose can help patients
sion. Delay of IL-10 treatment for one hour after cisplatin also
who are refractory to lower doses of cisplatin [4]. Treat-significantly inhibited renal damage. IL-10 and -melanocyte
ment of patients with peritoneal carcinomatosis, an in-stimulating hormone (-MSH) increased recovery following
curable stage is cancer, is quite difficult. Surgical debulk-transplantation of a kidney subjected to warm ischemia. To
explore the mechanism of action of IL-10, its effects were ing, followed by cisplatin administered via continuous
measured on mediators of leukocyte trafficking and inducible hyperthermic peritoneal perfusion shows promise for
nitric oxide synthase (NOS-II). IL-10 inhibited cisplatin and treatment of peritoneal mesothelioma [5]. However, dose-
ischemia-induced increases in mRNA for tumor necrosis
limiting nephrotoxicity occurs with doses above 90 mg/factor- (TNF-), intercellular adhesion molecule-1 (ICAM-1),
m2 IV or 270 mg/m2 IP, despite adequate hydration andand NOS-II. IL-10 also inhibited staining for markers of apo-
the administration of systemic sodium thiosulfate to bindptosis and cell cycle activity following cisplatin administration,
and nitric oxide production in cultured mouse cortical tubules. systemically absorbed cisplatin. Because the dose limit-
Conclusions. IL-10 protects against renal ischemic and cis- ing toxicity of regionally administered intraperitoneal
platin-induced injury. IL-10 may act, in part, by inhibiting the cisplatin is systemic nephrotoxicity, strategies that allowmaladaptive activation of genes that cause leukocyte activation
dose escalation may result in improved efficacy. Methodsand adhesion, and induction of iNOS.
to prevent cisplatin-induced ARF might minimize treat-
ment morbidity and interruptions in therapy.
1 These three authors contributed equally to this work. Whereas N-acetyl-cysteine has been recently shown
to decrease renal injury from radiocontrast-induced ARF
Key words: ischemia-reperfusion injury, inflammation, leukocytes, re-
[6], no therapeutic agents are available to prevent ARFnal transplantation, nitric oxide synthase, alpha-melanocyte stimulating
hormone. following ischemia, other nephrotoxic agents, or trans-
plantation. We recently found that the anti-inflammatoryReceived for publication May 7, 2001
cytokine -melanocyte stimulating hormone (-MSH)and in revised form July 5, 2001
Accepted for publication July 9, 2001 protects against renal ischemia reperfusion injury even
when started six hours after ischemia [7]. -MSH inhibits 2001 by the International Society of Nephrology
2118
Deng et al: IL-10 inhibits acute renal injury 2119
both maladaptive inflammatory and cytotoxic (nitric ox- temperature. Both renal pedicles were cross-clamped for
ide) pathways activated during the reperfusion period. 40 minutes. Both kidneys were inspected for ischemia
The anti-inflammatory cytokine interleukin-10 (IL-10) after two minutes. IL-10, -MSH or vehicle (0.5 mL)
is a potent inhibitor of fever, early-phase inflammation, was given at the end of the ischemic period immediately
and has many effects similar to -MSH including inhibi- before the clamps were removed. After the clamps were
tion of cytokines, chemokines, neutrophil activation, and removed, the kidneys were again inspected for restora-
nitric oxide (NO) production [8]. IL-10 has been shown tion of blood flow, and 1 mL of prewarmed (37C) normal
recently to inhibit ischemia-reperfusion injury to the lung saline was instilled into the abdominal cavity. The abdo-
[9, 10], hind limb [11], and heart [12]. men was closed, and the animals were placed in a 29C
Because of similarities between cisplatin and ischemic- incubator overnight. The animals were sacrificed at 24
induced renal injury [13, 14], we tested the hypothesis hours. At the time of sacrifice, blood was collected for
that IL-10 inhibits both ischemic and cisplatin-induced measurement of plasma creatinine (Beckman Astra 8
renal injury. We also tested the effects of IL-10 (and autoanalyzer; Beckman Industries, Inc.; Fullerton, CA,
-MSH) in a model that mimics transplantation of a USA). Both kidneys were harvested for histological
marginal kidney. study or mechanistic studies. Sham-treated animals went
through the same surgical procedure as the other ani-
mals, including dissection of the renal pedicle; however,METHODS
renal clamps were not applied.Animals
Male BALB/c and C57BL/6J were purchased from Histological examination
Jackson Labs (Bar Harbor, ME, USA), Harlan Sprague- Formalin (10%)-fixed and paraffin-embedded kidney
Dawley Inc. (Indianapolis, IN, USA) or the National specimens were stained with hematoxylin and eosin
Institutes of Health (NIH). All animals had free access (H&E; 2 m) or naphthol AS-D chloroacetate esterase
to water and food (4% mouse-rat diet, Harlan Sprague- (Sigma Kit # 91-C, 3 m sections). Histological changes
Dawley Inc.; or NIH-07 rodent chow, Zeigler Bros. Inc., were evaluated by semiquantitative measurements of tis-
Gardners, PA, USA) before surgery, and a lower K diet sue necrosis and erythrocyte congestion as described pre-
after surgery that supplied 50% the potassium of the viously [7, 15]. Since the esterase stain identifies both
normal diet, as previously [15]. Animal care followed the infiltrating neutrophils and macrophages [16], the term
criteria of the University of Texas Southwestern Medical leukocytes will be used through the rest of this article.
Center and NIH for the care and use of laboratory ani-
Leukocyte infiltration was measured by counting five highmals in research.
power fields (40) per section. TUNEL (Kit 1 684 809;
Boehringer Mannheim, Mannheim, Germany) and PCNAChemicals
(Kit 93-1143, Zymed Laboratories, Inc.) staining wasInterleukin-10 was purchased from PharMingen (San
carried out using the manufacturer’s recommended proto-Diego, CA, USA); -MSH was purchased from Phoenix
col using 4% paraformaldehyde-fixed tissue; the PCNAPharmaceuticals, Inc. (Mountain View, CA, USA). All
slides were lightly counterstained with methyl green.other chemicals were purchased from Sigma Chemical
Corp. (St. Louis, MO, USA). Measurement of mediator mRNA by RT-PCR
Reverse transcription-polymerase chain reaction (RT-Cisplatin
PCR) was performed as described previously [17, 18].The mice were anesthetized with an IM injection of
Briefly, renal total RNA was purified using guanidinium100 mg/kg ketamine, 10 mg/kg xylazine, and 1 mg/kg
thiocyanate-phenol-chloroform extraction [19]. cDNAacepromazine. The animals were given 20 mg/kg cisplatin
was generated from kidney RNA samples by Molony(Sigma) in 20 mL/kg normal saline IP, and then IL-10,
murine leukemia virus (MMLV) reverse transcriptase.-MSH or vehicle (0.5 mL) was given IV. Blood was
Portions of the cDNA were amplified by PCR primerswithdrawn at 48 and 72 hours; the animals were sacrificed
directed toward mouse tumor necrosis factor- (TNF-),at 72 to 96 hours. At the time of sacrifice, blood was
intracellular adhesion molecule-1 (ICAM-1), or nitriccollected for measurement of plasma creatinine. Both
oxide synthase-II (NOS-II) (Table 1). PCR conditionskidneys were harvested for histological and mechanistic
were Mg 2.5 mmol/L, annealing temperature 58C, andstudies.
35 cycles. The PCR products were confirmed by sequenc-
Ischemia-reperfusion model ing. These conditions resulted in a single band with a
linear relationship between cDNA and PCR product.Surgery was performed as previously described [7, 15].
We normalized for amount of RNA by measuring MDHThe mice were anesthetized with ketamine, xylazine, and
in separate PCR reactions. The PCR products were elec-acepromazine as above. The animals were placed on a
heating table kept at 39C to maintain constant body trophoresed through 1.5% agarose.
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Table 1. Sequences of oligonucleotide primers
Location Product size
Gene Bank
Gene identifier Oligonucleotide sequence bp
Mouse MDH (M29462)
5 sense GGTCATTGTTGTGGGAAACC (456–475) 431
3 antisense TCGACACGAACTCTCCCTCT (867–886)
Mouse TNF- (M38296)
5 sense GAACTGGCAGAAGAGGCACT (32–50) 211
3 antisense AGGGTCTGGGCCATAGAACT (242–261)
Mouse ICAM-1 (M31585)
5 sense AGATCACATTCACGGTGCTG (533–552) 252
3 antisense CTTCAGAGGCAGGAAACAGG (784–803)
Mouse NOS-II (M87039)
5 sense TGCATGGACCAGTATAAGGCAAGC (1948–1971) 223
3 sense GCTTCTGGTCGATGTCATGAGCAA (2147–2170)
Genes are identified by GeneBank abbreviations. Abbreviations are: bp, base pair; MDH, malate dehydrogenate; ICAM-1, intercellular adhesion molecule-1;
NOS-II, inducible nitric oxide synthase-II; TNF-, tumor necrosis factor-.
Renal transplantation grown in RPMI 1640 medium supplemented with penicil-
lin, streptomycin, and 10% heat-inactivated fetal bovineMale Lewis rats weighing 300 g were used for both
serum (FBS; Atlanta Premium Select, Atlanta Biologics,the kidney donor and transplant recipient. After the induc-
Norcross, GA, USA). RAW 264.7 cells were maintainedtion of anesthesia (sodium pentobarbital, 30 mg/kg IP),
in Dulbecco’s modified Eagle’s medium (DMEM) sup-the donor rat was placed on a warm operating pad and
plemented with 4.5 g/L glucose, non-essential aminothe abdomen was entered via a midline incision. A small
acids, 4 mmol/L l-glutamine, penicillin, streptomycin,clip was placed on the left renal pedicle and the renal
and 10% heat-inactivated FBS. MCT and RAW cellsblood flow was completely occluded. After 40 minutes,
were seeded in 96-well microplates at concentrations ofthe clip was released and the kidney was reperfused for
1.2  104 and 7.5  104 cells per 100 L per well. The30 minutes. A clamp was placed on the aorta above the
cells were incubated for 30 hours at 37C in 5% CO2/renal arteries and both donor kidneys were flushed with
3 mL ice-cold University of Wisconsin (UW) solution air. MCT cells were treated after 30 hours with 0.35
via a 27-gauge needle. The left kidney and ureter were U/mL mouse interferon- (IFN-) with vehicle, 0.35
harvested and kept in UW solution at 4C overnight. nmol/L -MSH, or 0.35 ng/mL IL-10 in an additional
Recipient surgery. After anesthesia, the recipient rat’s 100L complete-RPMI/well. The RAW cells were treated
abdomen was entered via a midline incision. The abdom- after 30 hours with 10 ng/mL lipopolysaccharide (LPS;
inal aorta and vena cava were dissected free and clamped E. coli 026:B6; Sigma) with vehicle, 0.35 nmol/L -MSH,
with a Sun Lee clamp. The donor kidney was implanted or 0.35 ng/mL IL-10 in an additional 100 L complete
to the aorta and vena cava in an end-to-side fashion DMEM/well. The treated cells were incubated for an
with 9-0 nylon suture. Then the clamp was released and additional 16 to 20 hours at 37C. Nitrite concentrations
homeostasis achieved. The donor ureter was anasto- were determined with Greiss reagent using NaNO2 as a
mosed to the recipient bladder with a pull-through tech- standard [15]. All assays were performed using three to
nique. Both kidneys of the recipient were subsequently four replicates, and repeated in at least four independent
removed. The abdomen was closed and the animal was experiments.
repleted with 3 to 5 mL saline via the penile vein. The
animals were kept in a 29C incubator overnight while Statistical analysis
recovering from surgery.
All data presented as mean  SEM. Different treat-Administration of drugs. Interleukin-10 was adminis-
ments were compared using ANOVA techniques (com-tered to the recipient rats as a single 1.5 g IV dose
pletely randomized design) followed by Dunnett’s testimmediately after the implantation of the donor kidney.
for individual comparisons between group means. TheAlpha-MSH was given as multiple 150 g doses IV at
null hypothesis was rejected when P  0.05.0, 6, and 16 hours after the implantation of donor kidney.
The animals also received similar doses of -MSH BID
on the second post-operative day, and on the morning RESULTS
of the third post-operative day.
Effect of IL-10 on renal function following
cisplatin administrationCell culture
In preliminary studies, the dose dependency of IL-10Mouse cortical tubule (MCT) and RAW 264.7 cells
were grown as described in [15]. Briefly, MCT cells were was investigated in male BALB/c and C57BL/6 mice
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Fig. 1. Dose dependency of interleukin-10 (IL-10) on renal function
following cisplatin administration in (A) BALB/c and (B) C57BL6 mice.
Animals were given 20 mg/kg cisplatin IP, and either vehicle or 0.1, 0.5
or 1 g IL-10 by IV injection at the time of cisplatin administration (3
to 5 BALB/c and 2 C57BL/6 mice per group). Blood was obtained at
48 and 72 hours. Animals were sacrificed at 72 hours. Data are mean 
1 SE. *P  0.05 vs. no IL-10 by ANOVA.
using plasma creatinine at 48 and 72 hours as an end
Fig. 2. Effect of IL-10 on renal function following cisplatin administra-point. We found that 1 g of IL-10 given with cisplatin
tion. BALB/c mice received IP cisplatin and vehicle () or 1 g IL-10
produced maximal inhibition of cisplatin-induced renal by IV injection at the time of cisplatin administration (). Data are
mean  1 SE. N 	 8 to 10 animals per group. *P  0.05.injury in both strains of mice (Fig. 1). A more extensive
study in BALB/c mice (Fig. 2) demonstrated that 1 g
IL-10 significantly decreased renal injury when given at
the time of cisplatin administration. Effect of IL-10 following renal ischemia/reperfusion
Figure 6 shows the effect of administering 0.5 g IL-10Effect of IL-10 histologic damage following
or vehicle IV to BALB/c mice immediately after removalcisplatin administration
of the vascular clamps. IL-10 administration significantlyTo determine if the functional changes were associated
reduced renal injury, as assessed by plasma creatininewith histologic evidence of protection, histologic changes
24 hours after ischemia. Ischemic kidneys showed wide-
at 72 hours after cisplatin were investigated. Cisplatin
spread necrosis and sloughing of the proximal straight
caused necrosis of proximal convoluted and straight tu-
tubule with obstructing casts (Fig. 3C) and accumulation
bules, casts, and leukocyte accumulation (Fig. 3A). IL-10 of leukocytes between tubules in the outer stripe of the
significantly decreased cisplatin-induced necrosis and in- outer medulla. There was also erythrocyte congestion in
traluminal cast formation (Fig. 3B). The histologic changes the inner stripe of the outer medulla (not seen in Fig.
were measured using semiquantitative scales (0 to 3
) 3C). In contrast, kidneys of mice treated with IL-10 had
for tubular necrosis, casts, and erythrocyte congestion, less necrosis of the proximal straight tubule (Fig. 3D)
and quantitative counts of the number of neutrophils and decreased leukocyte plugging. The histologic changes
(Fig. 4). IL-10 inhibited tubule necrosis, cast formation, were measured by semiquantitative scores of necrosis
erythrocyte congestion, and leukocyte accumulation. and congestion, and by counting the number of leuko-
cytes (Fig. 7). IL-10 significantly reduced the outer and
Delayed IL-10 administration inner stripe necrosis and outer stripe leukocyte infiltra-
Most therapeutic agents have a “golden window of tion, although there was no significant change in inner
opportunity” beyond which they are not effective. For stripe congestion.
example, Kelly et al found that ICAM-1 antibody is not
Effect of -MSH and IL-10 following transplantationeffective when therapy is delayed for one hour [13]. In
of a kidney subjected to warm ischemiacontrast, IL-10 was still effective when treatment was
delayed by one hour following cisplatin administration The effects of IL-10 alone and in combination with
-MSH were tested in a second species using a clinicallyin both BALB/c and C57BL/6 mice (Fig. 5).
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Fig. 3. Typical histology and leukocyte accu-
mulation following cisplatin administration.
Mice were studied 72 hours after cisplatin (A,
B) or 24 hours after 40 minutes of ischemia
(C, D). Mice were treated with vehicle (A, C)
or IL-10 (B, D). Sections stained with H&E.
relevant model of renal transplantation from a marginal whereas inhibition of ICAM-1 inhibits cisplatin-induced
donor. The rat donor kidney was clamped for 40 minutes, injury [13, 20–24]. We found that IL-10 inhibited the
reperfused for 30 minutes, flushed with preservation so- induction of TNF-, ICAM-1, and NOS-II mRNA abun-
lution, stored overnight in cold preservation solution, dance after either cisplatin administration (Fig. 9, top)
and then transplanted into the same strain of rats. As or ischemia (Fig. 9, bottom). Cisplatin and ischemia both
would occur clinically, -MSH and IL-10 were given only increase apoptosis and cause proliferation of tubule cells
to the recipient rats. We found that both agents alone, [25–27]. IL-10 decreased the number of TUNEL (a mea-
and in combination, increased recovery of renal function sure of apoptosis; terminal deoxy transferase uridine tri-
following transplantation (Fig. 8) that was particularly phosphate nick end-labeling), and PCNA (a measureevident on days 2, 3, and 5. There was no statistically
of cell cycle activity; proliferating cell nuclear antigen)significant synergy between the two agents on days 2
positive cells at day 3 following cisplatin administrationand 3.
(Fig. 4). The TUNEL positive cells were located in corti-
Mechanism of action cal tubules between medullary rays, presumably proxi-
mal convoluted tubules. The PCNA positive cells werePrevious studies have shown that inhibition of TNF-,
ICAM-1, or NOS-II inhibits ischemia/reperfusion injury, located in damaged tubules in the outer stripe.
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Fig. 4. Effects of IL-10 on semiquantitative histology and quantitative
leukocyte accumulation, TUNEL, and PCNA staining in BALB/c mice
following cisplatin administration. A description of the methodology is
in the Methods section. Symbols are: () vehicle; ( ) IL-10. Data are
mean  1 SE. Number of animals are 4 to 8 cisplatin, and 3 cisplatin 

IL-10. *P  0.05 vs. vehicle.
Fig. 6. Effect of IL-10 on renal function following ischemic injury.
BALB/c mice were subjected to 40 minutes of ischemia, received vehicle
or 0.5 g IL-10 IP after clamp release, and sacrificed after 24 hours.
Number of animals are 3 sham, 5 ischemia, and 6 ischemia 
 IL-10.
*P  0.05.
Fig. 7. Effects of IL-10 on semiquantitative histology and quantitative
leukocyte counts in BALB/c mice subjected to 40 minutes of ischemia.
A description of the methodology is in the Methods section. Data are
Fig. 5. Effect of delayed IL-10 on renal function following cisplatin mean  1 SE. Number of animals are 3 sham, 5 ischemia, and 6
administration. Animals received 1 g IL-10 IV one hour after cisplatin. ischemia 
 IL-10. Symbols are: () vehicle; ( ) IL-10; *P  0.05 vs.
Data are mean  1 SE. Data from BALB/c mice are displayed as vehicle.
circles; C57BL/6 mice are shown as squares; open symbols are vehicle
and closed symbols are IL-10. *P  0.05.
cells and MCT cells (Fig. 10). The inhibition was similar
Effects of IL-10 in proximal tubule cells in vitro to that caused by -MSH as previously described [15].
-Melanocyte stimulating hormone inhibits nitric ox-
DISCUSSIONide production in macrophages and mouse cortical tu-
bule (MCT) cells [15, 17]. To test if IL-10 inhibited the Interleukin-10, initially denoted cytokine synthesis in-
induction of nitric oxide in MCT cells, cells derived from hibitory factor, was originally identified as an activity
mouse cortical proximal tubules were used. As a positive produced by Th2 helper T cells that inhibited cytokine
control, we tested IL-10 in RAW macrophage cells synthesis by Th1 helper cells in the presence of mono-
known to respond to IL-10 [28]. IL-10 inhibited LPS/ cytes-macrophage antigen presenting cells. This effect
was found to be indirect via inhibitory actions on macro-interferon-–stimulated nitrite production in both RAW
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Fig. 8. Effect of -melanocyte stimulating hormone (-MSH), inter-
leukin-10 (IL-10), or both agents on recovery from transplantation of
a kidney subjected to 40 minutes of warm ischemia. Six to 7 animals
per group; details are in the text. Symbols are: ( ) vehicle; () -MSH;
() IL-10; () -MSH 
 IL- 10. P  0.05 vs. vehicle by ANOVA for
-MSH on days 2, 3, and 5; IL-10 on days 2, 5, 7; MSH and IL-10 on
days 2, 3, and 5.
Fig. 9. Effect of IL-10 on mRNA abundance of TNF-, intracellular
phages [29]. IL-10 is a pleotrophic cytokine with many adhesion molecule-1 (ICAM-1), and inducible nitric oxide synthase
(NOS-II) following cisplatin administration or ischemia/reperfusion.immunosuppressive effects, and a few immuno-stimula-
Top: Animals were administered 20 g/kg cisplatin IV, given vehicletory effects [reviewed in [30]. IL-10 is also a potent anti-
or 1 g IL-10 IV, and then sacrificed at 4 hours. The RNA was ex-
inflammatory cytokine that suppresses the activation of tracted, and RT/PCR performed as described in the Methods section.
Bottom: Animals were subjected to 40 minutes of ischemia, givenneutrophils and monocytes, and their production of che-
vehicle or 1 g IL-10 IV, and then sacrificed at 30 minutes to 4 hours.mokines, cytokines, and nitric oxide in animals and hu-
mans [8, 31–33]. Thus, IL-10 acts at multiple sites in the
inflammatory cascade. IL-10 inhibits tissue injury, neu-
trophil mediated inflammation, and induction of iNOS. both inflammatory, cytotoxic, and apoptotic pathways of
Exogenous IL-10 decreases death from endotoxin sepsis renal injury. (3) In contrast to many other agents, IL-10
[34, 35], and prevents tissue injury in a wide variety of was effective even when started after cisplatin. The sig-
animal models. In humans, pretreatment with IL-10 at- nificance of these findings is discussed in the next section.
tenuates endotoxin-induced fever, proinflammatory cy-
Effect of IL-10 on renal injurytokine production, and neutrophil accumulation in lungs
[33]. Unfortunately, when given 30 minutes after endo- Acute renal injury from ischemia/reperfusion and cis-
toxin, IL-10 has limited effects. IL-10 inhibits neutrophil platin are known to share many common features, includ-
migration and LPS-induced cytokine (IL-1, TNF-) and ing similar histologic changes [necrosis of the proximal
chemokine (IL-8) release [32, 36, 37]. IL-10 inhibits neu- straight tubule, cast formation, and leukocyte accumula-
trophil-mediated tissue injury in hind limb [11], visceral tion], gene induction [ICAM-1, TNF-], and gene repres-
[38], and lung [9] ischemia models. IL-10 also decreases sion [pre-pro-EGF] [13, 41, 42]. Several studies have sug-
LPS-stimulated neutrophil accumulation in humans [33]. gested that cisplatin causes renal ischemia, because of
IL-10 inhibits the production of iNOS in whole animals changes in renal hemodynamics, leukocyte accumulation
and macrophages [32, 34, 39, 40]. IL-10 knockout mice in the outer stripe of the outer medulla, and protection
have unregulated production of NO following LPS infu- by the vasodilator verapamil [13, 14, 43]. Finally, inhibi-
sion, which contributes to the high mortality [34]. Taken tion of ICAM-1 decreases renal injury and leukocyte
together, there is abundant evidence that IL-10 inhibits infiltration in both models [13, 22-24, 44]. Since IL-10
neutrophil and iNOS pathways that cause tissue injury. also inhibits neutrophil infiltration [8], IL-10 was tested
This study found that (1) IL-10 decreased renal injury in both cisplatin and ischemia models. We found that a
in three different models of renal injury (cisplatin, isch- single injection of IL-10 inhibited renal damage based on
emia, transplantation of a marginal kidney) in two spe- its ability to inhibit rises in plasma creatinine following
cies (mouse and rat) and two different mouse strains cisplatin administration in BALB/c and C57BL/6 mice
(Figs. 1 and 2). IL-10 also demonstrated marked protec-(BALB/c and C57BL/6). (2) IL-10 dramatically inhibited
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ing transplantation of a marginal donor kidney (Fig. 8).
While there was a trend toward protection at 24 hours,
a statistically significant protective effect may have been
obscured by the intensity of renal damage (plasma creati-
nine near 5 mg/dL at 24 hours). Although some of the
effects of -MSH may be mediated by IL-10 [45], we
used this severe model of injury to test for synergy,
which might imply that the two agents have different
mechanisms of action. We did not detect significant syn-
ergy; however, we did not optimize either -MSH or IL-
10 dosage regimens in this model. IL-10 and -MSH
could either inhibit a second wave of renal injury or
accelerate the repair process, akin to growth factors that
only minimally inhibit renal damage as assessed at 24
hours, but accelerate repair [46, 47]. This issue cannot
be resolved since we did not obtain renal biopsies at 24
to 48 hours post-transplant. However, it is unlikely that
IL-10 enhanced recovery following cisplatin administra-
tion, since IL-10 decreased cell cycle activity measuredFig. 10. Effect of IL-10 and -MSH on nitrite production from mouse
by PCNA labeling (Fig. 4).cortical tubule cells or RAW 264.7 cells. MCT cells were stimulated
with IFN-. RAW cells were simulated with LPS. All assays were Taken together, IL-10 reduces renal ischemia-reperfu-
performed using 3 to 4 replicates, and repeated in at least 4 independent sion and cisplatin-induced injury in two mice strains andexperiments. *P  0.05 vs. control. The control and -MSH data were
enhances recovery following renal transplantation in apublished previously [15]. Symbols are: () control; () IL-10; ( )
-MSH. second species (rat). The degree of renal protection of
IL-10 is similar to that found in lung [9, 10], hind limb
[11], and heart [12] ischemia-reperfusion models. IL-10
treatment has some advantages over several recently
tion from renal dysfunction following ischemia reperfu- described therapeutic agents, either because of enhanced
sion injury (Figs. 6 and 8). These effects were confirmed effectiveness or more prolonged window of opportunity.
at the histologic level; IL-10-treated kidneys had less ne- In the setting of ischemia, IL-10 is more effective than
crosis of proximal tubules in both models (Figs. 3, 4 and anti-ICAM-1 antibodies [22], 1 acid glycoprotein [48],7). IL-10 inhibited erythrocyte accumulation following 1-antitrypsin [48], A2a adenosine receptor blockers [49],cisplatin (Fig. 4) but not following ischemia (Fig. 7). The or a poly(ADP-ribose) polymerase inhibitor [50] based
reasons and pathophysiological significance for this dis- upon the degree of reduction in creatinine at 24 hours.
parity are unknown. Erythrocyte accumulation is largely IL-10 may be as effective as a soluble P-selectin ligand
secondary to plugging of the ascending vasa recta by leu- [51] or antisense oligonucleotides to inducible nitric ox-
kocytes, with accentuation by egress of plasma water due ide synthase [52]; however, these agents had to be per-
to high pressure or increased capillary permeability. IL-10 fused directly into the renal artery, or given 30 minutes
had a numerically greater percent inhibition of leukocyte to 8 hours before ischemia. In the cisplatin model, IL-10
accumulation in the cisplatin model than in the ischemia is as effective as disopyramide or verapamil [53], ebselen
model, thus potentially leaving more blockages in the [54], methimazole [55] or melatonin [56], although these
ischemic vasa recta. However, the ischemia protocol was drugs had to be started 30 to 240 minutes before cisplatin.
performed using a smaller dose of IL-10; the 0.5 g dose IL-10 is more effective than glycine [57] and as effective
of IL-10 was also less effective that the 1 g dose in the as hepatocyte growth factor (HGF), but HGF required
cisplatin model (Fig. 1). Also, a single dose of IL-10 may dosing every six hours [58].
not have been sufficient for the cisplatin model, as there
Mechanism of actionwas a rise in creatinine from day 3 to day 5 (Fig. 2).
Since we did not perform extensive dose optimization Interleukin-10 inhibited leukocyte accumulation in
studies in either model, some of these small differences both ischemia and cisplatin models (Figs. 3, 4, and 7);
may be caused by different doses employed. therefore, our study initially focused on cytokines and
We also tested IL-10 in a second species (rat) using a adhesion molecules that cause leukocyte infiltration in
more clinically relevant model of renal ischemia, that is, acute inflammation, increase rapidly after ischemia, and
transplantation of a marginal kidney. A single dose of IL- blockade reduces renal injury [41, 59]. For example, TNF-
10 and/or six doses of -MSH given either individually or activates neutrophils and monocytes-macrophages. Re-
nal TNF- mRNA and protein are rapidly increasedtogether increased the recovery of renal function follow-
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within 30 minutes and one hour after ischemia, and neu- that part of IL-10’s actions occur via inhibition of NOS-II
induction by ischemia or cisplatin. Whether the inductiontralization of TNF- reduces damage and leukocyte ac-
cumulation after ischemia [20, 21, 24, 51]. Leukocyte occurs by the initial injury (ischemia or cisplatin) per se
or by subsequent events (that is, cytokines) initiatedadherence to endothelial cells is promoted by ICAM-1
expressed on endothelial cells. ICAM-1 mRNA is in- during the subsequent waves of injury is unknown.
duced after both ischemia and cisplatin administration;
Effect on apoptosis and cell cycle activityblocking ICAM-1 by neutralizing antibody or knockout
mice reduces renal damage and leukocyte infiltration Apoptosis and cell proliferation are increased follow-
ing both ischemia and cisplatin-induced renal injury [26,after ischemia or cisplatin administration [13, 22–24, 44,
51]. After confirming that TNF- mRNA abundance 27, 67]. We found that IL-10 reduced the number of posi-
tive staining cells in both the TUNEL assay (a markerwas rapidly increased after ischemia (Fig. 9, top), the
previous findings were extended to show that TNF- for apoptosis) and in the PCNA assay (a marker of cell
cycle activity) following cisplatin administration (Fig. 4).is also increased after cisplatin administration (Fig. 9,
bottom). IL-10 inhibited induction of TNF- mRNA The inhibition of TUNEL assay would be expected if
there was less injury, and hence, less response of the kid-abundance in both ischemia and cisplatin models, an
effect seen previously in activated macrophages and mes- ney to injury, as occurs following scavenging of free radi-
cals with dimethylthiourea [27], or prevention of ischemicangial cells [60, 61], and in peripheral blood monocytes
from patients with psoriasis receiving IL-10 [62]. We injury with -MSH [68]. IL-10 decreased the number of
PCNA positive cells following cisplatin administration,found that ICAM-1 mRNA is dramatically increased
one hour after renal ischemia, and four hours after cis- suggesting that IL-10 treated kidneys have less cell cycle
activity, which may be linked to its cytoprotective effects.platin (Fig. 9). IL-10 inhibited induction of ICAM-1
mRNA after ischemia or cisplatin (Fig. 9), as seen pre- This finding also indicates that IL-10 is unlikely to en-
hance tissue repair following cisplatin administration.viously following immune complex lung injury [63]. In-
duction of both TNF- and ICAM-1 occur early after Further studies, for example, at different time points in
both models of injury, would be needed to solidify theseischemia, before many leukocytes accumulate in the kid-
ney [7, 16, 51, 64, 65], suggesting that these two mediators conclusions.
are produced by intrinsic kidney cells to attract leuko-
IL-10 is effective when administered after cisplatincytes to the kidney. In addition to these indirect effects
on leukocyte function, IL-10 also directly inhibits neutro- The timing of cisplatin administration is easy to deter-
mine, and hence, there is sufficient time for patients tophil and macrophage function (Fig. 10 and [8, 60]). Thus,
IL-10 may have such dramatic effects on both ischemic- receive non-specific preventive strategies such as hydra-
tion, mannitol, and/or furosemide [69]. However, theseand cisplatin-induced renal injury because of its direct
(leukocyte) and indirect (cytokine, adhesion molecule) therapies are not always successful and medication errors
could prevent correct prophylaxis from being delivered,effects. Taken together, the above findings indicate that
IL-10 inhibits the activation of genes that promote leuko- so an effective therapy that can be started after adminis-
tration of cisplatin would be useful. Knowledge of thecyte activation, adhesion, and function, and that this in-
hibits an acute inflammatory response that occurs follow- window of opportunity can aid in understanding the
mechanism of action. IL-10 was protective even whening renal ischemia and cisplatin administration.
Ischemia induces NOS-II, and inhibition of NOS-II administration is begun one hour after cisplatin (Fig. 3),
reminiscent of the protective effects of -MSH wheneither by antisense oligonucleotides or knockout mice
decreases renal damage following renal ischemia [52, 66]. started six hours after ischemia [7]. This suggests that
injury does not occur because of cisplatin administrationIn contrast, the role of NOS-II following cisplatin admin-
istration is unknown. Since IL-10 inhibits induction of per se, but is a consequence of the maladaptive activation
of injury pathways such as TNF-, ICAM-1 and NOS-nitric oxide production [28], we examined the effect of
IL-10 on renal NOS-II following cisplatin and found that II. Delayed administration of ICAM-1 antibodies or gly-
cine do not protect against cisplatin-induced renal injuryNOS-II was induced following cisplatin (Fig. 9, top).
Furthermore, IL-10 inhibited both ischemic and cis- [13, 57]. Each of these agents may inhibit one injury
pathway that is protective if started early enough; how-platin-induction of NOS-II (Fig. 9). Since IL-10 inhibits
induction of NOS-II in cultured mouse RAW cell macro- ever, evidently both -MSH (following ischemia) and
IL-10 (following cisplatin) have a broader spectrum ofphages and mouse cortical tubules (Fig. 10), this suggests
that these stresses induce NOS-II via a common pathway activity against injury pathways. If these injury pathways
are not activated, as occurs with IL-10 following cis-that is inhibited by IL-10. IL-10 is likely to inhibit the
transcription of NOS-II, since NOS-II is primarily regu- platin-administration (or -MSH following ischemia)
then renal injury does not ensue. Alternatively, IL-10lated by transcription. That IL-10 also inhibits NOS-II
induction in vivo and NO production in vitro suggests may promote recovery of cellular function, perhaps by
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